Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Cost of Revenue readings, the most recent being $20.8 million for Q1 2026.

  • On a quarterly basis, Cost of Revenue rose 16.39% to $20.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $80.6 million, a 18.19% increase, with the full-year FY2025 number at $77.7 million, up 27.52% from a year prior.
  • Cost of Revenue hit $20.8 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $20.9 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $20.9 million in Q4 2025 to a low of $491000.0 in Q1 2023.
  • Median Cost of Revenue over the past 5 years was $10.6 million (2024), compared with a mean of $12.3 million.
  • Biggest five-year swings in Cost of Revenue: crashed 88.36% in 2023 and later surged 2055.4% in 2024.
  • Kiniksa Pharmaceuticals International's Cost of Revenue stood at $6.7 million in 2022, then skyrocketed by 42.83% to $9.6 million in 2023, then soared by 86.73% to $17.9 million in 2024, then rose by 17.04% to $20.9 million in 2025, then dropped by 0.71% to $20.8 million in 2026.
  • The last three reported values for Cost of Revenue were $20.8 million (Q1 2026), $20.9 million (Q4 2025), and $20.3 million (Q3 2025) per Business Quant data.